Researchers in Japan have identified a surprising candidate for tackling one of Alzheimer’s disease’s most persistent biological features: the sticky protein clumps known as amyloid-beta.
A new study reports that oral doses of the amino acid arginine—already widely used as a safe medication for other conditions—can disrupt these toxic aggregates in animals and may even reverse some of the resulting neurological damage.
Protein Build-up Dropped, Fewer Behavior Abnormalities
The team, led by neuroscientists at Kindai University and Japan’s National Institute of Neuroscience, tested arginine in male mice genetically engineered to develop Alzheimer’s-like amyloid-beta plaques. When the animals received arginine in their drinking water, the protein build-up in their brains dropped sharply.
The mice also showed fewer behavioral abnormalities and lower activity in genes linked to neuroinflammation—suggesting that the treatment may be doing more than simply clearing deposits.
“Our study demonstrates that arginine can suppress amyloid-beta aggregation both in vitro and in vivo,” said lead scientist Yoshitaka Nagai. “What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive.”
Alzheimer’s And Promising Step
The researchers also observed similar effects in fruit fly models, as well as in laboratory test-tube experiments. These results build on previous evidence that arginine can act as a “chemical chaperone,” helping prevent misfolded proteins from sticking together. Importantly, earlier animal studies show that arginine can cross the blood-brain barrier, a major hurdle for most experimental Alzheimer’s drugs.
While the findings mark a promising step, experts caution that much more research is needed before considering human trials. The mice received relatively high doses of arginine, and scientists still do not know what level—if any—would be safe or effective for people. There is also ongoing scientific debate over whether removing amyloid-beta plaques meaningfully slows or stops Alzheimer’s progression in humans.
Still, the study offers a tantalizing possibility: that a well-known, low-cost molecule might someday play a role in treating neurodegenerative diseases rooted in protein misfolding.
“Given its excellent safety profile and low cost, arginine could be rapidly translated to clinical trials for Alzheimer’s and potentially other related disorders,” Nagai said. “Our findings open up new possibilities for developing arginine-based strategies for neurodegenerative diseases caused by protein aggregation.”
About The Author
